UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 245

Sortiert nach

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification

Leukemia, 2024-02, Vol.38 (2), p.442-445

2024

Volltextzugriff (PDF)

Assessing in vitro dermal absorption of dry residues of agrochemical sprays using human skin within OECD TG 428

Regulatory toxicology and pharmacology, 2019-08, Vol.106, p.55-67

2019

Volltextzugriff (PDF)

Who Classification 2016 for the Myelodysplastic Syndromes (MDS): Main Changes

Leukemia research, 2017-04, Vol.55, p.S77-S77

2017

Volltextzugriff (PDF)

Assessment of in vitro human dermal absorption studies on pesticides to determine default values, opportunities for read-across and influence of dilution on absorption

Regulatory toxicology and pharmacology, 2014-04, Vol.68 (3), p.412-423

2014

Volltextzugriff (PDF)

P772: PROGNOSTIC IMPACT OF DISEASE‐RELATED RISK FACTORS AND TREATMENT APPROACHES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS)

HemaSphere, 2022-06, Vol.6, p.667-668

2022

Volltextzugriff (PDF)

I-005 WHO 2013

Leukemia research, 2013-05, Vol.37, p.S2-S2

2013

Volltextzugriff (PDF)

Transfusion Need and Comorbidities are Independent Prognostic Parameters in Low Risk MDS Patients

Leukemia research, 2017-04, Vol.55, p.S148-S148

2017

Volltextzugriff (PDF)

Myelodysplastic Syndromes Showing Slight Monocytic Marrow Proliferation Are Prone to Progress to CMML

Leukemia research, 2017-04, Vol.55, p.S79-S79

2017

Volltextzugriff (PDF)

Assessment of an extended dataset of in vitro human dermal absorption studies on pesticides to determine default values, opportunities for read-across and influence of dilution on absorption

Regulatory toxicology and pharmacology, 2015-06, Vol.72 (1), p.58-70

2015

Volltextzugriff (PDF)

P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY

HemaSphere, 2022-06, Vol.6, p.666-667

2022

Volltextzugriff (PDF)

W. Otterspeer (ed.), De hand van Huizinga

Bijdragen en mededelingen betreffende de geschiedenis der Nederlanden, 2011-01, Vol.126 (2), p.138-139

Strupp, C.

2011

Volltextzugriff (PDF)

Chronic myelomonocytic leukemia in the light of the WHO proposals

Haematologica (Roma), 2007-07, Vol.92 (7), p.974-977

2007

Volltextzugriff (PDF)

Patients with IPSS-R Intermediate Risk can be Separated Into Three Risk Groups

Leukemia research, 2017-04, Vol.55, p.S147-S147

2017

Volltextzugriff (PDF)

Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup

Annals of hematology, 2005-09, Vol.84 (9), p.569-571

2005

Volltextzugriff (PDF)

317 ASXL1 MUTATION IS ASSOCIATED TO LOWER PLATELET COUNTS AND DECREASED BONE MARROW CELLULARITY IN MDS

Leukemia research, 2015-04, Vol.39, p.S157-S157

2015

Volltextzugriff (PDF)

240 DYSPLASIAS REVISITED – CONSIDERATIONS FOR A MULTIDIMENSIONAL APPROACH TO HETEROGENEITY OF MDS: DATA ON 1979 PATIENTS FROM THE GERMAN AUSTRIAN DATA BASE

Leukemia research, 2015-04, Vol.39, p.S119-S119

2015

Volltextzugriff (PDF)

Modeling a Thermoelectric HVAC System for Automobiles

Journal of electronic materials, 2009-07, Vol.38 (7), p.1093-1097

2009

Volltextzugriff (PDF)

P-093 Hypoplastic myelodysplastic syndromes are not a specific clinical entity

Leukemia research, 2013-05, Vol.37, p.S63-S63

2013

Volltextzugriff (PDF)

P-255 Inclusion criteria of clinical trials do not meet the real MDS population. A registry-based simulation

Leukemia research, 2013-05, Vol.37, p.S137-S138

2013

Volltextzugriff (PDF)

119 UPDATE ON THE MULTICENTER MDS BIOREGISTRY PROJECT OF THE “KREBSHILFE-VERBUNDFORSCHUNGSPROJEKT MDS” OF THE GERMAN MDS STUDY GROUP

Leukemia research, 2015-04, Vol.39, p.S61-S62

2015

Volltextzugriff (PDF)

P-049 Clinical and prognostic relationship of CMML to MDS and MPS

Leukemia research, 2013-05, Vol.37, p.S44-S44

2013

Volltextzugriff (PDF)

P22-27: Toxicity of 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors: converging evidence from in vivo and a new approach method invitrothat mouse is the most relevant test species

Toxicology letters, 2023-09, Vol.384, p.S254-S255

2023

Volltextzugriff (PDF)

P009 Incidence and prevalence of myelodysplastic syndromes (MDS) in Duesseldorf 1996–2005

Leukemia research, 2009-05, Vol.33, p.S62-S63

2009

Volltextzugriff (PDF)

124 - Who Classification 2016 for the Myelodysplastic Syndromes (MDS): Main Changes

Leukemia research, 2017-04, Vol.55, p.S77-S77

2017

Volltextzugriff (PDF)

295 Validation of the WHO 2008 classification for ‘non-blastic’ myelodysplastic syndromes. Lumping or splitting?

Leukemia research, 2011, Vol.35, p.S116-S116

2011

Volltextzugriff (PDF)

1 – 25 von 245

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(194)
Mit Volltextzugriff
(211)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(79)
Humans
(67)
Life Sciences & Biomedicine
(64)
Neurosciences & Neurology
(29)
Neurosciences
(25)
Animals
(23)
Female
(22)
Hematology, Oncology And Palliative Medicine
(22)
Biological And Medical Sciences
(21)
Clinical Neurology
(18)
Multidisciplinary Sciences
(17)
Science & Technology - Other Topics
(17)
Medical Sciences
(16)
Adult
(10)
Neurology
(10)
Hematology
(9)
Dentistry
(8)
Middle Aged
(8)
Ophthalmology
(8)
Rats
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification

Assessing in vitro dermal absorption of dry residues of agrochemical sprays using human skin within OECD TG 428

Who Classification 2016 for the Myelodysplastic Syndromes (MDS): Main Changes

Assessment of in vitro human dermal absorption studies on pesticides to determine default values, opportunities for read-across and influence of dilution on absorption

P772: PROGNOSTIC IMPACT OF DISEASE‐RELATED RISK FACTORS AND TREATMENT APPROACHES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS)

I-005 WHO 2013

Transfusion Need and Comorbidities are Independent Prognostic Parameters in Low Risk MDS Patients

Myelodysplastic Syndromes Showing Slight Monocytic Marrow Proliferation Are Prone to Progress to CMML

Assessment of an extended dataset of in vitro human dermal absorption studies on pesticides to determine default values, opportunities for read-across and influence of dilution on absorption

P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY

W. Otterspeer (ed.), De hand van Huizinga

Chronic myelomonocytic leukemia in the light of the WHO proposals

Patients with IPSS-R Intermediate Risk can be Separated Into Three Risk Groups

Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup

317 ASXL1 MUTATION IS ASSOCIATED TO LOWER PLATELET COUNTS AND DECREASED BONE MARROW CELLULARITY IN MDS

240 DYSPLASIAS REVISITED – CONSIDERATIONS FOR A MULTIDIMENSIONAL APPROACH TO HETEROGENEITY OF MDS: DATA ON 1979 PATIENTS FROM THE GERMAN AUSTRIAN DATA BASE

Modeling a Thermoelectric HVAC System for Automobiles

P-093 Hypoplastic myelodysplastic syndromes are not a specific clinical entity

P-255 Inclusion criteria of clinical trials do not meet the real MDS population. A registry-based simulation

119 UPDATE ON THE MULTICENTER MDS BIOREGISTRY PROJECT OF THE “KREBSHILFE-VERBUNDFORSCHUNGSPROJEKT MDS” OF THE GERMAN MDS STUDY GROUP

P-049 Clinical and prognostic relationship of CMML to MDS and MPS

P22-27: Toxicity of 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors: converging evidence from in vivo and a new approach method invitrothat mouse is the most relevant test species

P009 Incidence and prevalence of myelodysplastic syndromes (MDS) in Duesseldorf 1996–2005

124 - Who Classification 2016 for the Myelodysplastic Syndromes (MDS): Main Changes

295 Validation of the WHO 2008 classification for ‘non-blastic’ myelodysplastic syndromes. Lumping or splitting?

Aktive Filter

Suchergebnisse filtern